Skip to Content
Morningstar
Get 14 Days Free
Stock Strategist Industry Reports

A Coronavirus Vaccine, or Three, Could Be Available by Year-End

We expect multiple approved vaccines by early 2021 with wide vaccine distribution in developed markets by mid-2021.

Karen Andersen
Mentioned: , , , , , , , , ,

Resurgences in COVID-19 outbreaks have made it clear that ending the pandemic will require more than diagnostics, contact tracing, and social distancing. It will require an effective vaccine and vaccine distribution.

  • We’re increasingly bullish that most of the vaccines entering late-stage development in the United States will meet Food and Drug Administration guidelines for approval. We expect the FDA could award three emergency use authorizations for use in high-risk individuals before the end of the year for Moderna (MRNA), Pfizer/BioNTech (PFE)/(BNTX), and AstraZeneca/Oxford (AZN), based on interim efficacy data from phase 3 studies. We expect most U.S. adults will be vaccinated in the first half of 2021.
  • We think the global COVID-19 vaccine market could surpass $40 billion in 2021, including at least $11 billion in U.S. government contracts at a $24 average price per course.
  • We still expect minimal vaccine profit from not-for-profit strategies at AstraZeneca and Johnson & Johnson (JNJ) and minimal long-term valuation impact for Big Pharma in general, given uncertainty surrounding duration of sales.

Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.